针对患者的教育 (ePRO-E) 在联盟临床试验 (A221805-SI1) 中增加ePRO意图
Ellen M Lavoie Smith1, Youmin Cho2, Shauna Hillman3
1Department of Acute, Chronic and Continuing Care, University of Alabama at Birmingham School of Nursing, Birmingham, AL, USA.
JNCI cancer spectrum
|January 17, 2024
概括
一个新的教育资源改善了癌症试验中的患者报告结果 (ePRO) 意图,但没有增加高质量的数据提交. 需要进一步的战略来提高ePRO数据质量.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 医疗信息学 医疗信息学
背景情况:
- 国家癌症研究所国家临床试验网络 (NCTN) 采用了Patient Cloud ePRO应用程序,用于电子患者报告结果 (ePRO) 数据收集.
- 在NCTN中观察到ePRO应用程序的使用率很低,因此需要制定改善采用和数据质量的策略.
研究的目的:
- 评估针对患者的ePRO教育资源 (ePRO-E) 在增加ePRO意图和改善NCTN研究中的数据质量的有效性.
- 评估技术态度对ePRO选择的影响.
主要方法:
- 一项前性研究将接触ePRO-E (书面材料和视频) 的干预组与历史控制组进行了比较.
- ePRO的意图和数据质量 (≥80%的调查提交) 是主要的结果,共变量包括技术态度,人口统计和并发症.
- 总共有69名参与者被纳入了比较.
主要成果:
- 与历史对照组 (47.1%) 相比,干预组显示出明显更高的ePRO意图 (78.8%).
- 具有更高技术态度的患者更有可能选择ePRO调查.
- 尽管意图增加,但ePRO组的数据提交率 (30.6%) 与纸质调查组 (57.9%) 相比明显较低.
结论:
- 通过ePRO-E干预,成功地提高了患者使用电子患者报告结果的意愿.
- 积极的技术态度与更高的ePRO采用有关.
- 需要采取额外的策略来提高临床试验中ePRO数据提交的质量和完整性.
相关概念视频
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
183
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
183


